What is the HAS-BLED Score?
The HAS-BLED score is a clinical prediction tool used to estimate the risk of major bleeding in patients with atrial fibrillation (AF) who are being considered for or already receiving anticoagulation therapy. Developed by Pisters et al. in 2010 and published in the journal Chest, it was derived from data in the Euro Heart Survey on Atrial Fibrillation, which included 3,978 patients with AF.
The acronym HAS-BLED stands for Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (>65), and Drugs/alcohol concomitantly. Each letter represents a risk factor that contributes one point to the total score, with two letters (A and D) representing two criteria each, yielding a maximum possible score of 9.
The HAS-BLED score has been endorsed by the European Society of Cardiology (ESC) guidelines and is widely used in clinical practice to inform anticoagulation decisions. It is important to note that a high HAS-BLED score does not necessarily mean anticoagulation should be withheld; rather, it highlights modifiable risk factors that can be addressed to reduce bleeding risk while maintaining the benefits of stroke prevention.
Atrial Fibrillation & Anticoagulation
Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting approximately 33 million people worldwide. It is characterized by irregular and often rapid heart rate caused by disorganized electrical signals in the upper chambers (atria) of the heart. The most feared complication of AF is stroke, which occurs because blood can pool in the poorly contracting atria and form clots that travel to the brain.
Anticoagulation therapy — using medications like warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban — dramatically reduces the risk of stroke in AF patients. However, all anticoagulants carry an inherent risk of bleeding, ranging from minor bruising to life-threatening hemorrhage. The clinical challenge lies in balancing the benefit of stroke prevention against the risk of bleeding.
The CHA2DS2-VASc score is used to estimate stroke risk, while the HAS-BLED score assesses bleeding risk. Together, these tools help clinicians and patients make informed decisions about whether to initiate, continue, or modify anticoagulation therapy. In most cases, if the stroke risk exceeds the bleeding risk, anticoagulation is recommended even with an elevated HAS-BLED score.
Each Criterion Explained
H – Hypertension
Uncontrolled hypertension, defined as systolic blood pressure consistently above 160 mmHg, increases the risk of intracranial hemorrhage and other bleeding events. This criterion scores 1 point. Importantly, hypertension is a modifiable risk factor — improving blood pressure control can reduce this component of bleeding risk.
A – Abnormal Renal Function
Abnormal renal function is defined as chronic dialysis, renal transplant, or serum creatinine greater than 2.26 mg/dL (200 μmol/L). Impaired kidney function affects drug clearance, platelet function, and coagulation pathways, all of which increase bleeding risk. This criterion scores 1 point.
A – Abnormal Liver Function
Abnormal liver function includes chronic hepatic disease (such as cirrhosis), or biochemical evidence of significant hepatic derangement: bilirubin greater than 2 times the upper limit of normal in conjunction with AST/ALT/alkaline phosphatase greater than 3 times the upper limit of normal. The liver produces clotting factors, so hepatic dysfunction directly impairs hemostasis. This criterion scores 1 point.
S – Stroke History
A history of stroke (ischemic or hemorrhagic) or transient ischemic attack (TIA) scores 1 point. Prior cerebrovascular events indicate underlying vascular disease and an increased susceptibility to both ischemic and hemorrhagic events, particularly intracranial bleeding during anticoagulation.
B – Bleeding History or Predisposition
This includes any prior major bleeding event, anemia, or known bleeding diathesis (inherited or acquired bleeding disorder). A history of gastrointestinal bleeding, intracranial hemorrhage, or other significant hemorrhagic events significantly increases the likelihood of future bleeding on anticoagulation. This criterion scores 1 point.
L – Labile INR
Labile INR refers to unstable or high international normalized ratio (INR) values in patients on vitamin K antagonists (warfarin). It is typically defined as time in therapeutic range (TTR) less than 60%. Poor INR control is one of the strongest predictors of bleeding and is a modifiable risk factor. This criterion scores 1 point and applies only to patients on warfarin; it is not applicable to patients on direct oral anticoagulants (DOACs).
E – Elderly
Age greater than 65 years is associated with increased bleeding risk due to age-related changes in vascular fragility, organ function, and polypharmacy. This is a non-modifiable risk factor that scores 1 point.
D – Drugs Predisposing to Bleeding
Concomitant use of antiplatelet agents (aspirin, clopidogrel, prasugrel) or nonsteroidal anti-inflammatory drugs (NSAIDs) increases bleeding risk when combined with anticoagulation. This is a modifiable risk factor — discontinuing unnecessary antiplatelet agents or NSAIDs can reduce bleeding risk. This criterion scores 1 point.
D – Alcohol Excess
Excessive alcohol consumption, defined as 8 or more standard drinks per week, impairs liver function, platelet function, and medication adherence. It is a modifiable risk factor that scores 1 point.
Scoring & Risk Stratification
| Score | Risk Category | Bleeds per 100 Patient-Years | Recommendation |
|---|---|---|---|
| 0 | Low | 1.13 | Anticoagulation generally safe |
| 1 | Low | 1.02 | Anticoagulation generally safe |
| 2 | Moderate | 1.88 | Consider anticoagulation with caution, address modifiable risk factors |
| 3 | High | 3.74 | Careful assessment needed, address modifiable risk factors |
| 4 | High | 8.70 | High risk — closely monitor, consider alternatives |
| ≥ 5 | Very High | 12.50 | Extreme caution; specialist consultation recommended |
What is Major Bleeding?
Major bleeding in the context of anticoagulation is typically defined using the International Society on Thrombosis and Haemostasis (ISTH) criteria:
- Fatal bleeding
- Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome)
- Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more
- Bleeding leading to transfusion of 2 or more units of whole blood or red blood cells
The most feared forms of major bleeding are intracranial hemorrhage (which can be fatal or cause permanent disability) and gastrointestinal hemorrhage (which is more common but usually treatable). Direct oral anticoagulants (DOACs) have been shown to have lower rates of intracranial hemorrhage compared to warfarin, though gastrointestinal bleeding rates may be similar or slightly higher with some DOACs.
Anticoagulation Decisions
The HAS-BLED score should be used alongside the CHA2DS2-VASc score to guide anticoagulation decisions. Key principles include:
- A high HAS-BLED score is not a reason to withhold anticoagulation. The score identifies patients who need closer monitoring and modification of reversible risk factors.
- Modifiable risk factors should be addressed. Uncontrolled hypertension, labile INR, concomitant drugs, and alcohol excess can often be improved, reducing bleeding risk while maintaining stroke protection.
- DOACs may be preferred over warfarin in patients with labile INR, as they do not require INR monitoring and have more predictable pharmacokinetics.
- Regular reassessment is essential. Both stroke and bleeding risk can change over time, and risk scores should be recalculated periodically, especially when clinical circumstances change.
Comparison to Other Bleeding Scores
| Score | Criteria Count | Validated In | Key Feature |
|---|---|---|---|
| HAS-BLED | 9 | AF patients on anticoagulation | Most widely used; ESC-endorsed |
| ATRIA | 5 | AF patients on warfarin | Includes anemia and GFR criteria |
| ORBIT | 5 | AF patients on oral anticoagulation | Simpler; developed for DOAC era |
| HEMORR2HAGES | 11 | AF patients | More complex; includes genetic factors |
Among these tools, HAS-BLED has been the most extensively validated and is the most widely recommended in international guidelines. However, no single score perfectly predicts bleeding in individual patients, and clinical judgment remains essential.
Frequently Asked Questions
What does a HAS-BLED score of 3 or more mean?
A score of 3 or higher indicates high bleeding risk. However, this does not automatically mean anticoagulation should be stopped. It signals the need for careful monitoring, addressing modifiable risk factors (such as controlling blood pressure, stopping unnecessary NSAIDs, or improving INR stability), and possibly choosing a DOAC over warfarin.
Does the Labile INR criterion apply to patients on DOACs?
No. The labile INR criterion is only applicable to patients taking vitamin K antagonists (warfarin). For patients on DOACs (dabigatran, rivaroxaban, apixaban, edoxaban), this criterion should be scored as 0. Some clinicians assign 0 to this criterion when evaluating patients who are being considered for DOACs rather than warfarin.
Should I stop anticoagulation if my HAS-BLED score is high?
Generally, no. Guidelines consistently emphasize that a high HAS-BLED score should prompt risk factor modification and closer monitoring rather than withholding anticoagulation. In most patients with AF and a CHA2DS2-VASc score of 2 or higher (1 or higher in men), the stroke risk outweighs the bleeding risk, and anticoagulation remains beneficial.
How often should the HAS-BLED score be reassessed?
The HAS-BLED score should be reassessed at least annually or whenever there is a significant change in the patient's clinical status. New diagnoses, medication changes, or changes in alcohol consumption can all affect the score. Regular reassessment helps ensure that modifiable risk factors are identified and addressed promptly.
Is HAS-BLED validated for patients not on anticoagulation?
The HAS-BLED score was originally developed and validated in anticoagulated AF patients. While the underlying risk factors are relevant to bleeding risk in general, the specific bleeding rates and predictive accuracy may not directly translate to non-anticoagulated populations. Other tools may be more appropriate for assessing bleeding risk in different clinical contexts.